- Home
- CURX vs ALZN Comparison
CURX vs ALZN Comparison
Compare CURX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURX | ALZN |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.3M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CURX | ALZN |
|---|---|---|
| Price | $0.28 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.7M | 93.9K |
| Earning Date | 09-09-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.61 | $1.58 |
| 52 Week High | $8.60 | $10.35 |
Technical Indicators
Market Signals| Indicator | CURX | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 32.40 | 33.99 |
| Support Level | $0.27 | $1.58 |
| Resistance Level | $0.31 | $2.11 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 11.45 | 19.91 |
Price Performance
Historical ComparisonAbout CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.